UMediC Group Berhad Valuation

Is UMC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of UMC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: UMC (MYR0.7) is trading below our estimate of fair value (MYR1.18)

Significantly Below Fair Value: UMC is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for UMC?

Other financial metrics that can be useful for relative valuation.

UMC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5x
Enterprise Value/EBITDA17.4x
PEG Ratio1.2x

Price to Earnings Ratio vs Peers

How does UMC's PE Ratio compare to its peers?

The above table shows the PE ratio for UMC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average47.2x
G3 G3 Global Berhad
49.9xn/aRM94.3m
CENGILD Cengild Medical Berhad
20.8xn/aRM249.9m
DCHCARE DC Healthcare Holdings Berhad
107xn/aRM274.0m
FOCUSP Focus Point Holdings Berhad
11.2x11.0%RM337.3m
UMC UMediC Group Berhad
26.8x22.2%RM261.7m

Price-To-Earnings vs Peers: UMC is good value based on its Price-To-Earnings Ratio (26.8x) compared to the peer average (47.2x).


Price to Earnings Ratio vs Industry

How does UMC's PE Ratio compare vs other companies in the Asian Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a-7.7%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a-7.7%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: UMC is expensive based on its Price-To-Earnings Ratio (26.8x) compared to the Asian Healthcare industry average (21.8x).


Price to Earnings Ratio vs Fair Ratio

What is UMC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

UMC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio26.8x
Fair PE Ratio22.4x

Price-To-Earnings vs Fair Ratio: UMC is expensive based on its Price-To-Earnings Ratio (26.8x) compared to the estimated Fair Price-To-Earnings Ratio (22.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst UMC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentRM0.70
RM0.95
+36.4%
4.7%RM1.00RM0.91n/a2
Apr ’25RM0.63
RM0.95
+51.6%
4.7%RM1.00RM0.91n/a2
Dec ’24RM0.76
RM1.02
+34.4%
1.5%RM1.03RM1.00n/a2
Nov ’24RM0.72
RM1.02
+41.0%
1.5%RM1.03RM1.00n/a2
Oct ’24RM0.74
RM1.02
+36.2%
1.5%RM1.03RM1.00n/a2
Sep ’24RM0.80
RM1.02
+27.7%
1.5%RM1.03RM1.00n/a2
Aug ’24RM0.70
RM1.02
+45.0%
1.5%RM1.03RM1.00n/a2
Jul ’24RM0.72
RM1.02
+41.0%
1.5%RM1.03RM1.00n/a2
Jun ’24RM0.71
RM1.03
+44.1%
2.9%RM1.06RM1.00n/a2
May ’24RM0.81
RM1.03
+26.4%
2.9%RM1.06RM1.00RM0.702
Apr ’24RM0.80
RM1.03
+29.6%
2.9%RM1.06RM1.00RM0.632
Feb ’24RM0.76
RM0.47
-38.7%
33.7%RM0.78RM0.38RM0.635
Jan ’24RM0.68
RM0.47
-31.5%
33.7%RM0.78RM0.38RM0.705
Dec ’23RM0.72
RM0.47
-34.4%
35.8%RM0.81RM0.38RM0.765
Nov ’23RM0.64
RM0.47
-25.7%
35.8%RM0.81RM0.38RM0.725
Oct ’23RM0.80
RM0.47
-41.0%
35.8%RM0.81RM0.38RM0.745
Sep ’23RM0.63
RM0.43
-30.9%
20.7%RM0.61RM0.38RM0.805
Aug ’23RM0.55
RM0.43
-21.5%
20.7%RM0.61RM0.38RM0.705

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.